David Happel sold $497K of Sagimet Biosciences (SGMT)

Executed Jul 20, disclosed Jul 22, 2 days later.

Value, as filed

$497K

64,051 sh × $7.76

Executed

Jul 20

the trade date, as filed

Disclosed

Jul 22

2 days after the trade

Return, 21 sessionsiFrom the disclosed entry session; derived

–

purchases only

Returns are measured on stock purchases only.

The filer

David Happel President & CEO profile →

David Happel (President & CEO) filed 1 Form 4 report in the trailing twelve months (0 purchases, 1 sale), most often in Sagimet Biosciences Inc. (SGMT). The largest single filing was $497K of SGMT (64,051 sh × $7.76, as filed), executed Jul 20.

The name

SGMT

Sagimet Biosciences Inc. SGMT · Healthcare · 6 filings in 24 months ticker →

Healthcare · Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibit…

More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→

Other filings by David Happel in SGMT

SGMTSALE Sagimet Biosciences Inc. $598K
65,478 sh × $9.13
Exec Jul 21 2025
Filed Jul 23 2025 · 5:30 PM ET